Mutation resistant to tyrosine kinase inhibitors in chronic myeloid leukemia : about a case

Abstract

Introduction - The management and long-term outcome of patients affected by chronic myeloid leukemia (CML) hadimproved considerably with the introduction in the 2000’s of tyrosine kinase inhibitors, that revolutionized the prognosis of the disease and improved overall the survival of patients. However, failures are observed. The appearance of mutations in the tyrosine kinase domain of BCR-ABL1 protein constitutes an important cause of resistance to therapy and represents the most studied mechanism. Observation - Here, we report a 20 years old patient diagnosed in 2015 and followed for chronic myeloid leukemia in chronic phase. His biological monitoring was marked by primary resistance to tyrosine kinase inhibitors of 1st and 2nd generation (Imatinib, Dasatinib and Nilotinib).

Keywords

• CML
• TKI
• Resistance
• Mutation
• T315I
• Transplantation of stem cell hematopoetic